LB2102 demonstrated a manageable safety profile and encouraging clinical activity in solid tumors among heavily pretreated patients Responses ...
14dOpinion
Entering Aaron Rodgers' last run, Brendan Sorsby or another bold Steelers QB swing can't be ignored
The Steelers know what they don't want to be: limited. That's all they've been lately at the quarterback position, and there ...
As generic versions of its blockbuster drug Ofev (nintedanib) start to hit the market, Boehringer Ingelheim GmbH looks to have swerved the patent cliff, with European and Japanese regulators both ...
Preliminary results from Phase 1 data for LB2102 to reinforce early evidence of activity in solid tumors in a rapid oral presentation New data ...
Customer stories Events & webinars Ebooks & reports Business insights GitHub Skills ...
Customer stories Events & webinars Ebooks & reports Business insights GitHub Skills ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results